ArticleHeliyon2023
Cuproptosis-related genes prediction feature and immune microenvironment in major depressive disorder.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Bioinformatics Analysis of the Diagnostic Value of Copper and Zinc Metabolism-Related Genes in Major Depressive Disorder: An In Silico Multi-Cohort Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Cuproptosis: Biomarkers, Mechanisms and Treatments in Diseases.Molecules (Basel, Switzerland) · 2026Review
- Novel screening tool for psychiatric samples with major depressive disorder: a two-centre study.BMJ mental health · 2025Article
- CircSpna2 attenuates cuproptosis by mediating ubiquitin ligase Keap1 to regulate the Nrf2-Atp7b signalling axis in depression after traumatic brain injury in a mouse model.Clinical and translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) is a severe, unpredictable, ill-cured, relapsing neuropsychiatric disorder. A recently identified type of death called cuproptosis has been linked to a number of illnesses. However, the influence of cuproptosis-related genes in MDD has not been comprehensively assessed in prior study. Aim: This investigation intends to shed light on the predictive value of cuproptosis-related genes for MDD and the immunological microenvironment. Methods: GSE38206, GSE76826, GSE9653 databases were used to analyze cuproptosis regulators and immune characteristics. To find the genes that were differently expressed, weighted gene co-expression network analysis was employed. We calculated the effectiveness of the random forest model, generalized linear model, and limit gradient lifting to arrive at the best machine prediction model. Nomogram, calibration curve, and decision curve analysis were used to show the anticipated MDD's accuracy. Results: This study found that there were activated immune responses and cuproptosis-related genes that were dysregulated in people with MDD compared to healthy controls. Considering the test performance of the learned model and validation on subsequent datasets, the RF model (including OSBPL8, VBP1, MTM1, ELK3, and SLC39A6) was considered to have the best discriminative performance. (AUC = 0.875). Conclusion: Our study constructed a prediction model to predict MDD risk and clarified the potential connection between cuproptosis and MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.